Product overview
Retatrutide (LY3437943) is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Compared with dual agonists, this innovative triple-action mechanism may deliver greater weight-loss effects, increased energy expenditure, and enhanced hepatic fat oxidation.
In Phase II clinical trials, Retatrutide demonstrated an average weight reduction of 24.2% at 48 weeks. Phase III clinical trial TRIUMPH-4 reported average weight loss of approximately 28–29% at 68 weeks, alongside significant improvements in knee pain.
Additionally, Retatrutide has demonstrated promising benefits in reducing liver fat, lowering glycated hemoglobin (HbA1c) levels, and improving cardiovascular risk markers. Its reported adverse effects are primarily gastrointestinal in nature, similar to those associated with incretin-based therapies.
Retatrutide represents a new generation of advanced metabolic therapeutics.
This content is provided for research reference purposes only and should not be interpreted as health, clinical, or legal advice or guidance.
### **Benefits**
Supports appetite reduction and enhanced satiety; supports research into body weight and body fat reduction; improves blood glucose and insulin sensitivity markers; promotes energy expenditure and fat metabolism; may help improve lipid profiles and metabolic markers associated with fatty liver disease.
### **Usage Instructions**
For research or compliant clinical research use only. Typically administered via subcutaneous injection following reconstitution, by qualified professionals in accordance with an approved research protocol or medical guidance.
Dosage, dose escalation schedules, and treatment duration must be determined according to formal research protocols. A low starting dose followed by gradual titration is generally recommended in clinical research settings. Self-adjustment of dosage or prolonged use without appropriate supervision is not recommended.
In Phase II clinical trials, Retatrutide demonstrated an average weight reduction of 24.2% at 48 weeks. Phase III clinical trial TRIUMPH-4 reported average weight loss of approximately 28–29% at 68 weeks, alongside significant improvements in knee pain.
Additionally, Retatrutide has demonstrated promising benefits in reducing liver fat, lowering glycated hemoglobin (HbA1c) levels, and improving cardiovascular risk markers. Its reported adverse effects are primarily gastrointestinal in nature, similar to those associated with incretin-based therapies.
Retatrutide represents a new generation of advanced metabolic therapeutics.
This content is provided for research reference purposes only and should not be interpreted as health, clinical, or legal advice or guidance.
### **Benefits**
Supports appetite reduction and enhanced satiety; supports research into body weight and body fat reduction; improves blood glucose and insulin sensitivity markers; promotes energy expenditure and fat metabolism; may help improve lipid profiles and metabolic markers associated with fatty liver disease.
### **Usage Instructions**
For research or compliant clinical research use only. Typically administered via subcutaneous injection following reconstitution, by qualified professionals in accordance with an approved research protocol or medical guidance.
Dosage, dose escalation schedules, and treatment duration must be determined according to formal research protocols. A low starting dose followed by gradual titration is generally recommended in clinical research settings. Self-adjustment of dosage or prolonged use without appropriate supervision is not recommended.